Barclays Cuts Axon Enterprise (NASDAQ:AXON) Price Target to $682.00

Axon Enterprise (NASDAQ:AXON) had its target price reduced by Barclays from $702.00 to $682.00 in a report released on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on AXON. The Goldman Sachs Group reduced their price target on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price on the stock in a research report on Tuesday, January 6th. Piper Sandler lowered their price target on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating for the company in a research report on Wednesday. UBS Group cut their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Finally, Craig Hallum reaffirmed a “buy” rating and set a $820.00 target price on shares of Axon Enterprise in a research note on Wednesday. Sixteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $762.93.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $542.40 on Wednesday. The firm has a market capitalization of $43.61 billion, a price-to-earnings ratio of 356.84, a PEG ratio of 16.57 and a beta of 1.48. The stock has a fifty day moving average of $537.92 and a 200 day moving average of $625.54. Axon Enterprise has a 52 week low of $396.41 and a 52 week high of $885.91. The company has a quick ratio of 2.89, a current ratio of 2.53 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business had revenue of $796.72 million during the quarter, compared to analyst estimates of $755.29 million. During the same period in the prior year, the business earned $2.08 EPS. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. As a group, research analysts expect that Axon Enterprise will post 5.8 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In related news, insider Jeffrey C. Kunins sold 1,797 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total value of $968,996.31. Following the sale, the insider owned 83,485 shares in the company, valued at approximately $45,017,616.55. This trade represents a 2.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Joshua Isner sold 20,000 shares of Axon Enterprise stock in a transaction on Monday, December 8th. The stock was sold at an average price of $552.60, for a total value of $11,052,000.00. Following the completion of the sale, the president directly owned 249,502 shares of the company’s stock, valued at $137,874,805.20. The trade was a 7.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 58,040 shares of company stock valued at $32,251,738. Insiders own 4.40% of the company’s stock.

Institutional Trading of Axon Enterprise

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Stone House Investment Management LLC purchased a new stake in shares of Axon Enterprise in the 3rd quarter worth $29,000. New Millennium Group LLC purchased a new position in Axon Enterprise during the third quarter valued at $29,000. Darwin Wealth Management LLC bought a new stake in Axon Enterprise during the second quarter valued at about $37,000. Root Financial Partners LLC purchased a new stake in Axon Enterprise in the third quarter worth about $34,000. Finally, Creative Financial Designs Inc. ADV bought a new position in shares of Axon Enterprise in the fourth quarter worth about $28,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.